Sotera Health Co. 10-Q Summary: Q1 2026
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Sotera Health Co. is a global provider of sterilization solutions, lab testing, and advisory services. The company operates through three reportable segments: Sterigenics (terminal sterilization), Nordion (Co-60 supply and irradiation systems), and Nelson Labs (microbiological and analytical testing).
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Net Revenues | $280.0 million | $254.5 million |
| Net Income (Loss) | $26.6 million | ($13.3 million) |
| Adjusted Net Income | $52.4 million | $39.0 million |
| Adjusted EBITDA | $134.7 million | $121.8 million |
| Gross Margin | 52.5% | 53.2% |
| Cash and Cash Equivalents | $314.1 million | $344.6 million (Dec 31, 2025) |
| Long-Term Debt | $2.12 billion | $2.13 billion (Dec 31, 2025) |
| Weighted Avg Interest Rate | 6.62% | 7.56% |
Material Changes vs. Prior Period
- Revenue Growth: Total net revenues increased 10.0% year-over-year, driven by a 7.9% increase in service revenues and a 25.7% increase in product revenues. Organic growth was approximately 6.5% excluding foreign currency impacts.
- Profitability Turnaround: The company returned to profitability with $26.6 million in net income, compared to a $13.3 million loss in Q1 2025. This improvement was significantly aided by the absence of a $30.9 million Illinois EO litigation settlement recorded in the prior year.
- Expense Management: Amortization of intangible assets decreased by 80.2% ($12.3 million) due to assets fully amortized in May 2025. Interest expense decreased 15.0% due to lower variable rates and principal paydowns.
- Cash Flow: Operating cash flow decreased to $29.4 million from $55.5 million, primarily due to a $34.0 million cash payment for the Illinois EO litigation settlement. Investing cash outflows increased to $45.1 million due to higher capital expenditures ($46.2 million vs. $19.9 million).
Outlook, Risks, and Management Commentary
- Segment Performance: Sterigenics revenue grew 9.7% and Nordion grew 29.0% (driven by Co-60 harvest timing). Nelson Labs revenue declined slightly by 0.7% due to volume/mix headwinds.
- Litigation Risks: Significant ongoing exposure remains regarding Ethylene Oxide (EO) tort litigation in California, Georgia, Illinois, and New Mexico. While the company believes losses are not probable, future settlements are reasonably possible. Insurance coverage for these claims has been exhausted.
- Operational Risks: Key risks include supply chain disruptions for EO and Co-60, geopolitical instability, regulatory changes, and the impact of foreign currency fluctuations.
- Liquidity: The company maintains $591.7 million in availability under its Revolving Credit Facility and expects sufficient liquidity to meet obligations for the next 12 months.
Investor Verification Checklist
- Verify the status and potential financial impact of pending EO tort litigation in Georgia and California, specifically regarding the "Second General Causation Ruling" and upcoming trials.
- Confirm the sustainability of Nordion's revenue growth, which was heavily influenced by Co-60 harvest schedule timing.
- Monitor capital expenditure trends, which doubled year-over-year to $46.2 million, and assess the return on these investments.
- Review the company's ability to maintain profitability without the benefit of the one-time litigation settlement removal seen in the prior year comparison.
- Assess the impact of foreign currency translation on future earnings, given the significant $17.6 million loss in other comprehensive income due to currency translation.